Amryt Pharma PLC Result of AGM (5410D)
July 07 2016 - 6:54AM
UK Regulatory
TIDMAMYT
RNS Number : 5410D
Amryt Pharma PLC
07 July 2016
7 July, 2016
Amryt Pharma plc
("Amryt" or the "Company")
Result of AGM
Amryt Pharma plc (AIM: AMYT, ESM: AYP), the clinical stage
specialty pharma company focused on best in class treatments for
orphan diseases, announces that all resolutions put to shareholders
were duly passed at its Annual General Meeting held earlier
today.
Enquiries:
Amryt Pharma plc C/o FTI Consulting
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20
Shore Capital 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
+353 (1) 679
Davy 6363
ESM Adviser and Joint
Broker
John Frain, Anthony Farrell
+44 (0) 20
Stifel 7710 7600
Joint Broker
Jonathan Senior, Ben
Maddison
+44 (0) 20
FTI Consulting 3727 1000
Simon Conway, Brett Pollard
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or 'orphan' diseases. The Company
is building a diversified portfolio of commercially attractive,
best-in-class, propriety new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
Amryt's lead product, Episalvan(R), received marketing approval
for the treatment of partial-thickness wounds from the European
Commission in January 2016. Amryt intends to further develop
Episalvan(R) as a new treatment for Epidermolysis Bullosa ("EB"), a
rare and distressing genetic skin disorder affecting young children
for which there is currently no treatment. Amryt is currently
planning a phase III study of Episalvan(R) in EB, which has been
granted US and EU orphan drug designation.
Amryt's earlier stage products are focused on developing novel,
next generation somatostatin analogue ("SSA") peptide medicines for
patients with rare neuroendocrine diseases, where there is a high
unmet medical need. These include acromegaly and Cushing's
disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGEAPXXEFLKEEF
(END) Dow Jones Newswires
July 07, 2016 07:54 ET (11:54 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024